Healthcare Industry News: Leksell Gamma Knife
News Release - September 3, 2007
Elekta Demonstrates Commitment to Stereotactic Innovation at EANSGLASGOW, Scotland, Sept. 3 (HSMN NewsFeed) -- Leading neurosurgical device developer Elekta will feature the newest advances in neurosurgical diagnostic and treatment devices, along with clinical workflow solutions that make neurosurgery more effective and efficient at the European Association of Neurosurgical Societies (EANS) European Congress September 2-7, 2007. More than 1,000 neurosurgeons and related medical professionals will gather at the Scottish Exhibition & Conference Centre in Glasgow for the event.
Leksell Gamma Knife® Perfexion(TM) highlighted
Positioned at the entrance of the exhibition hall, Elekta will feature Leksell Gamma Knife® Perfexion(TM), a quantum leap in stereotactic radiosurgery. The revolutionary patented design of the new Leksell Gamma Knife Perfexion collimator system dramatically expands treatment reach, simplifying the process of treating multiple tumors in the same session. Leksell Gamma Knife Perfexion provides better dosimetry performance than any other competitive radiosurgical system currently on the market and is estimated to increase the number of patients that can benefit from Gamma Knife surgery by up to 40 percent.
In addition, Gamma Knife® surgery is a radiosurgical procedure that is specifically well suited for the treatment of brain metastases.
"Leksell Gamma Knife Perfexion offers brain metastasis treatment in less time than other radiosurgical devices. Feedback from the first users in France, the United Kingdom and the United States has been overwhelmingly positive. Professor Jean Regis, La Timone Hospital in Marseilles has published that it is possible to treat four brain metastases eccentrically located (frontal anterior, far lateral and posterior fossa) in less than two hours," says Rolf Kjellstrom, Vice President of Sales and Marketing, Neuro & Stereotactic Solutions, Elekta. "It treats brain tumors very efficiently, and because the treatment is non-invasive, patient recovery time is nonexistent or dramatically reduced compared with invasive surgery."
David A. Larson, M.D., Ph.D., Radiation Oncologist and Co-Medical Director at the Gamma Knife Program, Washington Hospital, adds, "Our increasing ability to control primary cancers creates increased urgency to detect and treat metastatic lesions. Naturally, we want to do so non-invasively when possible and with a resulting positive impact on quality of life. Leksell Gamma Knife Perfexion, a remarkably sophisticated instrument, can safely and efficiently radiate multiple targets in a single session, and will surely benefit many patients."
New Linux-based software makes workflow more efficient and saves cost
Also on display will be Elekta neurosurgery workflow solutions, including Leksell SurgiPlan®, Elekta's advanced image-based neurosurgical planning software, and GammaPlan® PFX(TM), a treatment planning system with remote capabilities that provides all the tools needed to make full use of the enhanced features of Leksell Gamma Knife Perfexion. Leksell SurgiPlan and Leksell GammaPlan are now Linux-based for more efficient workflow and lower cost to hospitals and clinics. Leksell SurgiPlan also has a new module for pre-planning, which enables flexible planning of procedures, and automatic optimization of image quality.
Elekta Neuromag® system provides real-time MEG brain mapping with high spatial resolution
Elekta also will be exhibiting Elekta Neuromag®, an advanced device for performing magnetoencephalography (MEG). With a MEG system, neurosurgeons, neurologists and other specialists are able to non-invasively register nerve cell activity in the brain in real time. The technology is used routinely for pre-surgical mapping and epilepsy investigations as well as in clinical research. Elekta Neuromag features the highly innovative and unique MaxFilter(TM) software that filters all magnetic interferences and artefacts, providing an analysis with more reliable data.
Elekta Neuromag® 306 MEG channels sensor array has higher density than any other system on the market, providing a better representation of brain activity than any other MEG system.
MEG offers functional mapping information and measurement of brain activity in real time with high spatial resolution, unlike Computer Tomography (CT) and Magnetic Resonance Imaging (MRI and fMRI), which only provide structural, anatomical, metabolic and indirect functional information.
Elekta committed to advanced neurosurgery solutions
Elekta, known as the pioneer and world leader in stereotactic neurosurgery, continues to widen the gap between itself and other medical technology companies with the development of advanced tools for precision cancer treatment. "Elekta offers the complete spectrum of stereotactic devices," says Kjellstrom, "and Elekta's commitment to innovation in neurosurgery is unmatched."
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include, among others, Leksell Gamma Knife® product line for non-invasive treatment of brain disorders, Elekta Axesse(TM) for Image guided Stereotactic treatments, and Elekta Synergy® for intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group became the world's largest supplier of oncology software.
Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approximately 2,000 employees, Elekta's corporate headquarters is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.